Vertex, once king of hep C category, bows out as new drugs eclipse Incivek

Biotech Vertex ($VRTX) has pulled the plug on work in the hepatitis C arena, an area it was expected to dominate with its Incivek until Gilead Sciences ($GILD) redefined the category with Sovaldi, a drug now expected to become the top seller of all time. Even with Incivek fading away, Vertex has continued work in the area, but yesterday said it would out-license its remaining hep C drug, VX-135, and focus its efforts on cystic fibrosis, FierceBiotech reports. Story | More

Suggested Articles

Novartis is taking its MBC campaign to Instagram with a newly launched video series as part of the five-year “Make Your Dialogue Count” effort.

FDA researchers uncover more concerns and fears among front-line workers and minority groups about a COVID-19 vaccine.

As COVID-19 vaccines advance, the FDA held an expert hearing Thursday to talk safety, efficacy, distribution plans and vaccine confidence—plus more.